Ypsomed announced today that, at its annual general meeting, its shareholders approved all proposals, including facility expansions.
Burgdorf, Switzerland-based Ypsomed develops drug delivery devices, including insulin pumps for those with diabetes. Its YpsoPump represents a leading offering as an automated insulin delivery system compatible with certain software and glucose monitors.
Board member Simon Michel confirmed the company’s commitment to Switzerland as a manufacturing location at the annual meeting. Ypsomed expects to create 200 new jobs in Burgdorf and Solothurn in the current financial year, on top of expansions elsewhere.
“In addition to expanding production in Schwerin [Germany] and setting up our own plant in China, we will continue to strengthen and expand our facilities in Switzerland,” said Michel.
Additionally, at the meeting, present members of the board approved the re-election of Gilbert Achermann. They also approved amendments to the Articles of Association and a long-term incentive plan.
“I would like to thank the shareholders for their trust,” Achermann said. “Ypsomed has the privilege of providing people with chronic conditions with vital therapies. I am delighted to be able to lead the company further down this path.”
More positives for Ypsomed
The bolstering of manufacturing follows about a year of positive developments across the board at Ypsomed. Here are some of the highlights:
- In April 2022, the company partnered with Abbott and Camdiab on automated insulin delivery.
- In October, the company unveiled a new autoinjector
- This past January, Ypsomed completed the sale of mail-order retailer for diabetes care DiaExpert. This sale allows the company to focus on the manufacture and sale of its own medical technologies.
- Just this month, Ypsomed and S3 Connected Health partnered on digital offerings.
